Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to -$1.08.

  • vTv Therapeutics' EPS (Basic) fell 2272.73% to -$1.08 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.27, marking a year-over-year increase of 2781.46%. This contributed to the annual value of -$3.2 for FY2024, which is 6705.39% up from last year.
  • Per vTv Therapeutics' latest filing, its EPS (Basic) stood at -$1.08 for Q3 2025, which was down 2272.73% from -$0.92 recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' EPS (Basic) ranged from a high of -$0.01 in Q2 2021 and a low of -$9.78 during Q4 2022
  • In the last 5 years, vTv Therapeutics' EPS (Basic) had a median value of -$0.88 in 2024 and averaged -$1.8.
  • Within the past 5 years, the most significant YoY rise in vTv Therapeutics' EPS (Basic) was 8571.43% (2021), while the steepest drop was 2740000.0% (2021).
  • Over the past 5 years, vTv Therapeutics' EPS (Basic) (Quarter) stood at -$8.19 in 2021, then decreased by 19.41% to -$9.78 in 2022, then surged by 82.92% to -$1.67 in 2023, then skyrocketed by 62.29% to -$0.63 in 2024, then crashed by 71.51% to -$1.08 in 2025.
  • Its EPS (Basic) was -$1.08 in Q3 2025, compared to -$0.92 in Q2 2025 and -$0.77 in Q1 2025.